StockData
Seres Therapeutics, Inc. logo

Seres Therapeutics, Inc. (MCRB) stock

MCRBNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 6/30
$1.41+0.00 (0.00%)

Close on Nov 17, 2026Market cap $14.02MP/E –Yield –

Seres Therapeutics cash

Cash and short-term investments held at the end of each period.

Seres Therapeutics's cash was $15.59M at Jun 30, 2026. For fiscal 2025 it was $45.77M, up 16.0% from the year before. Over ten years it grew -13.9% a year on average. The highest annual figure on record is $298.71M in fiscal 2021.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$45.77M+16.0%
FY2024Dec 31, 2024$39.46M-71.0%
FY2023Dec 31, 2023$136.15M-28.2%
FY2022Dec 31, 2022$189.53M-36.6%
FY2021Dec 31, 2021$298.71M+17.8%
FY2020Dec 31, 2020$253.62M+167.5%
FY2019Dec 31, 2019$94.82M+10.3%
FY2018Dec 31, 2018$85.93M-42.7%
FY2017Dec 31, 2017$150.10M-34.7%
FY2016Dec 31, 2016$230.00M+12.1%
FY2015Dec 31, 2015$205.08M+79.6%
FY2014Dec 31, 2014$114.19M+6803.6%
FY2013Dec 31, 2013$1.65M-73.4%
FY2012Dec 31, 2012$6.22M–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$15.59M-71.1%
Q1 FY2026Mar 31, 2026$29.83M-55.8%
Q4 FY2025Dec 31, 2025$45.77M+16.0%
Q3 FY2025Sep 30, 2025$47.64M-37.9%
Q2 FY2025Jun 30, 2025$54.05M-33.4%
Q1 FY2025Mar 31, 2025$67.52M-43.6%
Q4 FY2024Dec 31, 2024$39.46M-71.0%
Q3 FY2024Sep 30, 2024$76.70M-56.9%
Q2 FY2024Jun 30, 2024$81.11M-65.9%
Q1 FY2024Mar 31, 2024$119.61M+4.3%
Q4 FY2023Dec 31, 2023$136.15M-28.2%
Q3 FY2023Sep 30, 2023$178.10M-26.2%
Q2 FY2023Jun 30, 2023$237.71M+16.5%
Q1 FY2023Mar 31, 2023$114.73M-55.2%
Q4 FY2022Dec 31, 2022$189.53M-36.6%
Q3 FY2022Sep 30, 2022$241.19M-30.6%
Q2 FY2022Jun 30, 2022$203.98M-4.9%
Q1 FY2022Mar 31, 2022$256.19M-6.0%
Q4 FY2021Dec 31, 2021$298.71M+17.8%
Q3 FY2021Sep 30, 2021$347.39M+8.5%
Q2 FY2021Jun 30, 2021$214.55M+235.6%
Q1 FY2021Mar 31, 2021$272.55M+262.9%
Q4 FY2020Dec 31, 2020$253.62M+167.5%
Q3 FY2020Sep 30, 2020$320.31M+282.3%
Q2 FY2020Jun 30, 2020$63.94M-37.5%
Q1 FY2020Mar 31, 2020$75.09M+39.8%
Q4 FY2019Dec 31, 2019$94.82M+10.3%
Q3 FY2019Sep 30, 2019$83.79M+14.9%
Q2 FY2019Jun 30, 2019$102.34M+6.5%
Q1 FY2019Mar 31, 2019$53.71M-56.6%
Q4 FY2018Dec 31, 2018$85.93M-42.7%
Q3 FY2018Sep 30, 2018$72.90M-57.4%
Q2 FY2018Jun 30, 2018$96.10M-43.9%
Q1 FY2018Mar 31, 2018$123.71M-38.8%
Q4 FY2017Dec 31, 2017$150.10M-34.7%
Q3 FY2017Sep 30, 2017$171.30M-15.8%
Q2 FY2017Jun 30, 2017$171.21M–
Q1 FY2017Mar 31, 2017$202.17M–
Q4 FY2016Dec 31, 2016$230.00M–
Q3 FY2016Sep 30, 2016$203.38M–

More Seres Therapeutics figures

See a number that looks wrong?